Amol Akhade/hiranandanihospital.org
May 27, 2025, 03:04
Amol Akhade: New 1L HCC Data from China!
Amol Akhade, Consultant Medical Oncologist at the Suyog Cancer Clinics, posted on X:
“New 1L HCC Data from China!
HEPATORCH Trial (Phase 3):
Toripalimab + Bevacizumab vs Sorafenib
Median OS: 20.0 vs 15.3 mo | HR 0.76
Median PFS: 5.8 vs 3.7 mo | HR 0.69
ORR: 25.6% vs 5.5%
Grade ≥3 AEs: HTN (38%), Proteinuria (19%)
Now let’s compare With previous data in same space. Cross trial comparison is a SIN in oncology But that’s the ONLY sin we all do.”
More posts featuring Amol Akhade on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 27, 2025, 03:04
May 27, 2025, 02:32
May 27, 2025, 02:20
May 27, 2025, 02:15
May 26, 2025, 18:47